DK1502590T3 - Heterocykliske oximderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf ved behandling af diabetes type II - Google Patents

Heterocykliske oximderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf ved behandling af diabetes type II

Info

Publication number
DK1502590T3
DK1502590T3 DK04291901T DK04291901T DK1502590T3 DK 1502590 T3 DK1502590 T3 DK 1502590T3 DK 04291901 T DK04291901 T DK 04291901T DK 04291901 T DK04291901 T DK 04291901T DK 1502590 T3 DK1502590 T3 DK 1502590T3
Authority
DK
Denmark
Prior art keywords
diabetes
preparation
treatment
type
oxime derivatives
Prior art date
Application number
DK04291901T
Other languages
Danish (da)
English (en)
Inventor
Veronique Leclerc
Sylvie Pailloux
Pascal Carato
Carine Introvigne
Nicolas Lebegue
Catherine Dacquet
Jean Albert Boutin
Daniel Henri Caignard
Pierre Renard
Pascal Berthelot
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Application granted granted Critical
Publication of DK1502590T3 publication Critical patent/DK1502590T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DK04291901T 2003-07-28 2004-07-27 Heterocykliske oximderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf ved behandling af diabetes type II DK1502590T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0309214A FR2858321B1 (fr) 2003-07-28 2003-07-28 Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
DK1502590T3 true DK1502590T3 (da) 2007-04-10

Family

ID=33523001

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04291901T DK1502590T3 (da) 2003-07-28 2004-07-27 Heterocykliske oximderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf ved behandling af diabetes type II

Country Status (31)

Country Link
US (1) US7071221B2 (zh)
EP (1) EP1502590B1 (zh)
JP (1) JP4406331B2 (zh)
KR (1) KR100677013B1 (zh)
CN (1) CN100497323C (zh)
AR (1) AR045125A1 (zh)
AT (1) ATE348612T1 (zh)
AU (1) AU2004203454B2 (zh)
BR (1) BRPI0403028A (zh)
CA (1) CA2475137C (zh)
CY (1) CY1106336T1 (zh)
DE (1) DE602004003751T2 (zh)
DK (1) DK1502590T3 (zh)
EA (1) EA007718B1 (zh)
EG (1) EG24967A (zh)
ES (1) ES2279310T3 (zh)
FR (1) FR2858321B1 (zh)
GE (1) GEP20063896B (zh)
HK (1) HK1071748A1 (zh)
HR (1) HRP20070117T8 (zh)
MA (1) MA27104A1 (zh)
MX (1) MXPA04007257A (zh)
MY (1) MY139278A (zh)
NO (1) NO327257B1 (zh)
NZ (1) NZ534334A (zh)
PL (1) PL1502590T3 (zh)
PT (1) PT1502590E (zh)
SG (1) SG109010A1 (zh)
SI (1) SI1502590T1 (zh)
UA (1) UA80814C2 (zh)
ZA (1) ZA200405893B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009516730A (ja) * 2005-11-23 2009-04-23 アストラゼネカ アクチボラグ Ｌ−アラニン誘導体
FR2894965B1 (fr) * 2005-12-20 2008-01-25 Servier Lab Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2898125B1 (fr) * 2006-03-06 2008-06-13 Servier Lab Nouveaux derives heterocycliques cycloalkyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2009539815A (ja) * 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
FR2903404B1 (fr) * 2006-07-10 2008-08-22 Servier Lab Nouveaux derives tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2008093065A1 (en) * 2007-01-29 2008-08-07 Astrazeneca Ab L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
US9193767B2 (en) 2011-03-30 2015-11-24 Brown University Enopeptins, uses thereof, and methods of synthesis thereto
WO2016037072A2 (en) * 2014-09-04 2016-03-10 Brown University Enopeptin analogas and methods of use thereof
CN104725367B (zh) * 2015-03-13 2017-06-23 三峡大学 四氢苯并噻唑‑7‑酮肟药物，制备方法及其应用
CN104788436B (zh) * 2015-03-13 2018-05-01 三峡大学 四氢苯并呋喃-4-酮肟基三唑药物，制备方法及其应用
WO2018049068A1 (en) 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32769A (en) * 1861-07-09 Beehive
US4228292A (en) * 1978-07-20 1980-10-14 Monsanto Company N-Substituted benzothiazolines and benzoxazolines and their use as herbicides and plant growth regulants
DE3064910D1 (en) * 1979-06-12 1983-10-27 Fujisawa Pharmaceutical Co 2-oxo-benzothiazoline, benzoxazoline or indoline derivatives, their preparation, and pharmaceutical compositions comprising such derivatives
EP0719140B1 (en) * 1993-09-15 2007-10-31 Daiichi Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
SK111195A3 (en) * 1994-09-13 1997-06-04 Sandoz Technology Ltd Bicyclic ethers substituted with oxazole and thiazole, process for producing thereof and pharmaceutical composition containing same
FR2804431A1 (fr) * 2000-02-02 2001-08-03 Adir Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR0110428A (pt) * 2000-04-28 2003-06-17 Sankyo Co Composto ou um seu sal farmacologicamente aceitável, composição farmacêutica, usos de um composto ou um seu sal farmacologicamente aceitável, de um modulador de ppar gama e de um antagonista parcial, agentes que inibe a diferenciação de adipócitos, que acentua ou recupera a função osteogênica, para tratamento ou prevenção de osteoporose, que tem atividade moduladora de ppar gama, diminuidor do açúcar no sangue, para tratamento ou prevenção de diabetes melito, e, para tratamento ou prevenção
FR2830012B1 (fr) * 2001-09-21 2003-10-31 Servier Lab Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharamaceutiques qui les contiennent

Also Published As

Publication number Publication date
AU2004203454B2 (en) 2010-05-27
MA27104A1 (fr) 2004-12-20
EG24967A (en) 2011-03-13
HRP20070117T3 (en) 2007-04-30
PT1502590E (pt) 2007-02-28
JP4406331B2 (ja) 2010-01-27
DE602004003751T2 (de) 2007-10-18
SI1502590T1 (sl) 2007-04-30
GEP20063896B (en) 2006-08-10
DE602004003751D1 (de) 2007-02-01
EA200400867A2 (ru) 2005-02-24
KR100677013B1 (ko) 2007-01-31
CY1106336T1 (el) 2011-10-12
HK1071748A1 (en) 2005-07-29
MY139278A (en) 2009-09-30
EP1502590B1 (fr) 2006-12-20
US20050026973A1 (en) 2005-02-03
FR2858321B1 (fr) 2006-01-20
FR2858321A1 (fr) 2005-02-04
CN100497323C (zh) 2009-06-10
EA007718B1 (ru) 2006-12-29
EA200400867A3 (ru) 2005-04-28
CA2475137C (fr) 2010-04-06
ZA200405893B (en) 2005-01-24
KR20050013514A (ko) 2005-02-04
UA80814C2 (en) 2007-11-12
ES2279310T3 (es) 2007-08-16
SG109010A1 (en) 2005-02-28
US7071221B2 (en) 2006-07-04
HRP20070117T8 (en) 2007-07-31
EP1502590A1 (fr) 2005-02-02
BRPI0403028A (pt) 2005-06-14
JP2005047919A (ja) 2005-02-24
NZ534334A (en) 2005-12-23
MXPA04007257A (es) 2005-03-31
PL1502590T3 (pl) 2007-04-30
AU2004203454A1 (en) 2005-02-17
CA2475137A1 (fr) 2005-01-28
NO327257B1 (no) 2009-05-25
NO20043188L (no) 2005-01-31
CN1590379A (zh) 2005-03-09
ATE348612T1 (de) 2007-01-15
AR045125A1 (es) 2005-10-19

Similar Documents

Publication Publication Date Title
NO20053593D0 (no) Arylalkylkarbamat-derivater, fremgangsmate og anvendelse derav i terapi
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
NO20055204D0 (no) Derivater av piperidinyl- og pipemzinylalkylkarbamater, fremgangsmater for fremstilling derav og anvendelse av de samme i terapi
NO20055686L (no) Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav.
IS2733B (is) Afleiður af díoxan-2-alkýlkarbamötum, framleiðsluaðferð þeirra, milliefni notuð við framleiðsluna, og notkun þeirra í meðferð.
DK1824855T3 (da) Hidtil ukendte pyrrolo (3,2-d)pyrimidin-4-onderivater og anvendelser af disse til behandling
DK1524710T3 (da) Tynd batteristruktur, batterienhed og fremgangsmåde til fremstilling af batterienhed
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
DK1917246T3 (da) Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme
IS8026A (is) Mótefni gegn amýlóíðum, samsetningar, aðferðir ognotkun
DK1708994T3 (da) Aryloxyalkylcarbamatderivater, fremstilling og anvendelse herfra inden for terapi
DK1802749T3 (da) KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser
NO20054135D0 (no) Kipolinon/benzoksazin derivater og anvendelser derav
DK1603915T3 (da) Substituerede 8-pyridinyl-dihydrospiro-cycloalkyl-pyrimido- 1,2-a-pyrimidin-6-on og 8-pyrimidinyl-dihydrospiro-cycloalkyl-pyrimido-1,2-a-pyrimidin-6-on-derivater og deres anvendelse mod neurogenerative sygdomme
DK1651644T3 (da) Substituerede derivater af thiazol-benzoisothiazoldioxid, fremgangsmåde deraf og deres anvendelse
NO20054095D0 (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater
DK1511734T3 (da) Forbindelser, præparater og fremgangsmåder
IS8383A (is) Nýjar afleiður af 4a,5,9,10,11,12-hexahýdróbensófúró[3a,3,2][2]-bensasepín, aðferð við framleiðslu þeirra og notkun þeirra við framleiðslu á lyfjum
DK1753725T3 (da) Tetra-hydro-iso-quinolinsulfonamidderivater, fremstilling og terapeutisk anvendelse heraf.
DK1502590T3 (da) Heterocykliske oximderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf ved behandling af diabetes type II
DK1596868T3 (da) Fremgangsmåde til behandling af hjertesvigt og medikament dertil
DK1848440T3 (da) Farmaceutisk sammensætning og fremgangsmåde til regenerering af myofibre i behandlingen af muskelskader
DK1773829T3 (da) Aminotropanderivater, fremstilling og terapeutiske anvendelser heraf
DK1575951T3 (da) Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi